CurrentNeighborhood Health Plan of Rhode IslandPolicy 2003-A

Etanercept (Enbrel) — Coverage Criteria

Defines criteria, documentation, prescriber specialty, and prior authorization requirements for coverage of etanercept (Enbrel) for specified FDA-approved and compendial indications for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyEtanercept (Enbrel) — Coverage Criteria

Policy CodePolicy 2003-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionSubmit prior authorization with chart notes, prior medication history, relevant labs, and documentation of methotrexate trial or contraindication as applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

FDA & compendialIndications covered

3 monthsMethotrexate trial

12 monthsRA auth option

Do not combineNo concomitant biologic

within 12 moTB screening required

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Continuation and chronic‑indication authorization

Continuation and chronic‑indication authorization — Covered when ALL of the following are met for continuation or chronic‑indication authorization:

ALL of the following

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria.
Authorization of 12 months may be granted for members using the requested medication for chronic graft versus host disease who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.
Authorization of 12 months may be granted for members using the requested medication for Behcet's disease who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.
Authorization of 12 months may be granted for members using the requested medication for immune checkpoint inhibitor–related inflammatory arthritis who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition.

Safety and concomitant therapy exclusion

Safety and concomitant therapy exclusion — Covered when ALL of the following safety conditions are met:

ALL of the following

Member has had a documented negative tuberculosis (TB) test (tuberculin skin test [TST] or an interferon‑gamma release assay [IGRA]) within 12 months of initiating therapy for persons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB. If prior screening testing for TB is positive, further evaluation must confirm there is no active disease (e.g., chest x‑ray). For latent TB, TB treatment must be started before initiation of the requested medication.
Do not administer the requested medication to members with active tuberculosis (TB) infection.
Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

All other indications are considered experimental/investigational and not medically necessary.

Do not administer the requested medication to members with active tuberculosis infection.

Uses not listed among the FDA‑approved indications or the specified compendial uses are designated not medically necessary.

Key coding and clinical thresholds

Methotrexate trial requirements for RA

Required methotrexate trial duration3 months

Required methotrexate dose thresholdMaximum titrated dose of at least 15 mg per week

Acceptable alternative when MTX not toleratedUnable to tolerate 3-month MTX trial at max titrated dose documented

Combination therapy considerationDocumented inadequate response to MTX plus another conventional synthetic DMARD after 3-month trial at max tolerated doses

Tuberculosis screening recency

Acceptable TB testsTuberculosis skin test (TST) or interferon-release assay (IGRA)

Recency requirementTest performed within 12 months of initiating therapy for biologic/targeted-synthetic–naïve persons

Positive test follow-upIf positive, further testing to exclude active disease (e.g., chest x‑ray) and treatment for latent TB before initiation

Prior authorization, documentation, and provider requirements

Documentation Required

Required documentation for prior authorization

Submission of the following information is necessary to initiate the prior authorization review: Initial requests must include chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If a therapy was not tried for clinical reasons, provide documentation of the clinical rationale or contraindication (see Appendix A for examples). Also include relevant laboratory results or documentation of biomarker testing (e.g., RF, anti-CCP, CRP and/or ESR) when applicable, and documentation of affected area(s)/BSA for dermatologic indications when applicable. Continuation requests (including for new members transferring care) must include chart notes or medical record documentation supporting a positive clinical response and that the member continues to meet the coverage criteria.

Initial requests: chart notes, medical records, or claims history documenting prior medications tried and response, or documentation of clinical reason to avoid therapy (see Appendix A).
Laboratory results or documentation of biomarker testing when applicable (e.g., RF, anti-CCP, CRP and/or ESR).
Dermatologic indications: chart notes documenting affected area(s) and body surface area (BSA) when applicable.
Continuation requests (including transfers): chart notes or medical record documentation showing positive clinical response and ongoing benefit.

Documentation Required

TB screening and follow-up documentation

For members naïve to biologic or targeted synthetic agents, documentation of a negative tuberculosis (TB) screening test (TST or IGRA) within 12 months prior to initiating therapy is required. If TB screening is positive, additional evaluation (e.g., chest x-ray) must be performed to exclude active TB. Do not administer the requested medication to members with active TB. If latent TB is identified, TB treatment must be started before initiation of the requested medication.

Acceptable tests: tuberculosis skin test (TST) or interferon-gamma release assay (IGRA) within prior 12 months for biologic/targeted-synthetic–naïve members.
If screening positive: obtain confirmatory testing (e.g., chest x-ray) to rule out active disease.
Do not start therapy in active TB; begin latent TB treatment prior to therapy initiation.

Billing Rule

Dosing optimization and exceptions

Approvals may be subject to dosing limits per FDA labeling, compendia, and evidence-based guidelines. Dose optimization using 50 mg product formulations should be used when possible to minimize vial quantity. Exceptions allowing higher quantities of 25 mg vials will be permitted when the member has a documented latex allergy or when the member is receiving FDA‑approved weight‑based dosing.

Use 50 mg formulations for dose optimization when clinically feasible.
Allow additional 25 mg vials only for documented latex allergy or when following FDA‑approved weight‑based dosing regimens.
Approvals remain subject to overall dosing limits in FDA labeling and evidence-based guidance.

Definitions and referenced concepts

FDA‑approved indications for etanercept

Rheumatoid arthritis (RA)Moderately to severely active rheumatoid arthritis

Polyarticular juvenile idiopathic arthritis (pJIA)Moderately to severely active pJIA in patients 2 years of age and older

Psoriatic arthritis (PsA)Active psoriatic arthritis

Ankylosing spondylitis (AS)Active ankylosing spondylitis

Plaque psoriasis (PsO)Chronic moderate to severe plaque psoriasis in patients 4 years or older who are candidates for systemic therapy or phototherapy

Juvenile psoriatic arthritis (JPsA)Active JPsA in pediatric patients 2 years of age and older

Compendial (off‑label) uses considered covered

Non-radiographic axial spondyloarthritisIncluded as a compendial use considered covered when criteria are met

Oligoarticular juvenile idiopathic arthritisListed compendial use considered covered when criteria are met

Reactive arthritisCompendial use considered covered when criteria are met

Severe, refractory hidradenitis suppurativaCompendial use considered covered when criteria are met

Behcet's disease, graft versus host disease, immune checkpoint inhibitor-related toxicityListed compendial uses considered covered when criteria are met

Tuberculosis (TB) screening requirement

Definition of TB screeningDocumented negative tuberculosis test (TST or IGRA)

Recency for biologic‑naïve personsTest within 12 months of initiating therapy

Positive TB test actionsFurther testing to confirm no active disease (e.g., chest x‑ray) and start latent TB treatment prior to therapy

Dose optimization and allowed exceptions

Preferred product formulationUse 50 mg product formulations when possible

Exception — latex allergyHigher quantities of 25 mg vials allowed when the member has a latex allergy

Exception — weight‑based dosingHigher quantities of 25 mg vials allowed when following FDA‑approved weight‑based dosing

OpenPayer

Etanercept (Enbrel) — Coverage Criteria

Coverage criteria for etanercept (Enbrel)

Key coding and clinical thresholds

Prior authorization, documentation, and provider requirements

Definitions and referenced concepts

Background on etanercept